The emerging name in metabolic and inflammatory disease.

Disorders of metabolism are among the most common of human illnesses. Together, these conditions afflict virtually all organ systems and are typically chronic — if not lifelong — diseases. Management of these disorders usually requires prolonged treatment to avoid complications that lead to progressive disability, organ failure, and accelerated mortality.

Relburn is focused on the discovery and development of novel small molecules that favorably alter metabolic pathways in patients with these conditions leading to safe and sustained improvement of human health. The Company’s lead program is in inflammation.